Dr Marc P. Bonaca (University of Colorado School of Medicine, Aurora, Colorado, US) discusses DECLARE - TIMI 58 - dapagliflozin and outcomes in patients with peripheral artery disease.
Filmed on site at ACC 2019 by Radcliffe Cardiology.
00:08 - Please remind us of the DECLARE trial and data released at ACC 2018.
00:49 - Why did you conduct this sub-analysis and how many patients were analysed?
01:32 - What were your findings?
02:21 - What conclusions should be made as a result of this data?
03:19 - What other data can we anticipate out of the DECLARE-TIMI 58 study?
Videography: Josh Birch
Educational lead: Liam O'Neill - Chief Operating Officer